CO6290082A1 - Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b - Google Patents

Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b

Info

Publication number
CO6290082A1
CO6290082A1 CO10109151A CO10109151A CO6290082A1 CO 6290082 A1 CO6290082 A1 CO 6290082A1 CO 10109151 A CO10109151 A CO 10109151A CO 10109151 A CO10109151 A CO 10109151A CO 6290082 A1 CO6290082 A1 CO 6290082A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
salt
compartment
composition according
ketorolaco
Prior art date
Application number
CO10109151A
Other languages
English (en)
Inventor
Aguilar Juan Aurelio Senosiain
Lopez E Raul Salgado
Paniagua M Angelica Arzola
Hernandez Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CO6290082A1 publication Critical patent/CO6290082A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica para administración oral de comprimidos en tabletas caracterizada porque comprende:un primer compartimiento que comprende cantidades terapéuticamente efectivas de ketorolaco, vitamina B1, vitamina B12, o sus sales farmacéuticamente aceptables, vehículo de compresibilidad, aglutinante diluente, antiestático, lubricante, plastificante y desintegrante;un segundo compartimiento que comprende una cubierta o capa aislante formada de un polímero de recubrimiento; yun tercer compartimiento que comprende piridoxina o sus sales farmacéuticamente aceptables, y polímero ligante aglutinante. La composición farmacéutica de conformidad con la reivindicación 1 caracterizada porque comprende adicionalmente una cubierta final formada por un polímero de recubrimiento y acabado. La composición farmacéutica de conformidad con la reivindicación 1 caracterizada porque comprende de 2 a 120 mg de la sal de ketorolaco por unidad de dosis. La composición farmacéutica de conformidad con la reivindicación 1 caracterizada porque comprende de 0.2 a 6.0% de la sal de ketorolaco en peso de la composición.
CO10109151A 2008-03-07 2010-09-03 Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b CO6290082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008003230A MX2008003230A (es) 2008-03-07 2008-03-07 Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.

Publications (1)

Publication Number Publication Date
CO6290082A1 true CO6290082A1 (es) 2011-06-20

Family

ID=41055594

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10109151A CO6290082A1 (es) 2008-03-07 2010-09-03 Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b

Country Status (15)

Country Link
US (1) US20110059171A1 (es)
EP (1) EP2255803B1 (es)
AR (1) AR070542A1 (es)
BR (1) BRPI0908988A2 (es)
CA (1) CA2717900C (es)
CO (1) CO6290082A1 (es)
CR (1) CR11668A (es)
DO (1) DOP2010000265A (es)
EC (1) ECSP10010442A (es)
ES (1) ES2526359T3 (es)
HN (1) HN2010001775A (es)
MX (1) MX2008003230A (es)
PE (1) PE20091592A1 (es)
PL (1) PL2255803T3 (es)
WO (1) WO2009109836A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619344C1 (ru) * 2016-03-01 2017-05-15 Петр Александрович Попов Способ лечения невралгии
EP3366291A1 (en) * 2017-02-22 2018-08-29 Montero Gida Sanayi Ve Ticaret A.S. Solid oral pharmaceutical compositions comprising alpha lipoic acid and water-soluble vitamins
TR201702630A2 (tr) 2017-02-22 2018-09-21 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Alfa li̇poi̇k asi̇t ve suda çözünür vi̇tami̇nler i̇çeren oral farmasöti̇k bi̇leşi̇mler
CA3199162A1 (en) * 2020-12-04 2022-06-09 Cecilia Jannette Munoz Martinez Fixed-dose combination drug for the control and management of neuropathic pain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4492M (es) * 1965-07-07 1966-10-10
US4579846A (en) * 1984-10-11 1986-04-01 Pfizer Inc. Antiinflammatory compositions and methods
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
MXPA02010828A (es) * 2002-11-04 2004-07-16 Leopoldo Espinosa Abdala Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
US7335384B2 (en) * 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas

Also Published As

Publication number Publication date
PE20091592A1 (es) 2009-11-11
CA2717900C (en) 2016-05-10
EP2255803B1 (en) 2014-09-17
PL2255803T4 (pl) 2015-05-29
EP2255803A4 (en) 2011-06-29
US20110059171A1 (en) 2011-03-10
PL2255803T3 (pl) 2015-05-29
HN2010001775A (es) 2013-01-15
DOP2010000265A (es) 2010-09-30
AR070542A1 (es) 2010-04-14
ES2526359T3 (es) 2015-01-09
CR11668A (es) 2010-11-30
BRPI0908988A2 (pt) 2020-08-04
CA2717900A1 (en) 2009-09-11
WO2009109836A1 (es) 2009-09-11
ECSP10010442A (es) 2010-10-30
EP2255803A1 (en) 2010-12-01
MX2008003230A (es) 2009-09-07

Similar Documents

Publication Publication Date Title
AR066420A1 (es) Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
CO6400186A2 (es) Tabletas de acetato de ulipristal
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
BR112013009153A2 (pt) formulação de ligante de fosfato para dosagem única.
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
PA8669801A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
BR112012029064A2 (pt) formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan
CO6290082A1 (es) Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
JP2014504636A5 (es)
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
TR200903036A2 (tr) Tiyokolşikozit ve non-steroidal anti-enflamatuar ilaç kombinasyonları
BR112015012497A2 (pt) combinações farmacêuticas
ECSP11010999A (es) Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación

Legal Events

Date Code Title Description
FG Application granted